Detalhe da pesquisa
1.
Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Kidney Int
; 85(6): 1340-50, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24402093
2.
Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Nephrol Dial Transplant
; 28(2): 352-9, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23129826
3.
Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
Kidney Int
; 79(2): 234-40, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20944552
4.
Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant
; 24(11): 3334-42, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19525519
5.
Urinary biomarkers at early ADPKD disease stage.
PLoS One
; 10(4): e0123555, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25875363
6.
Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters.
PLoS One
; 7(7): e39229, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22859939
7.
Soluble klotho and autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol
; 7(2): 248-57, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22193235